Other Headlines

The DOTmed 100 company has a long tradition in medical technology.
Joint venture agreement with Japan's M-Cast, Inc., a subsidiary of leasing giant Mitsubishi UFJ Leasing and Finance.
RAND study confirms patients getting inaccurate information on physicians.
New KLAS report looks at smart pump adoption trends and the customer satisfaction gap among some products.
Members of MAGNET, a major U.S. healthcare group purchasing organization, can now order CARESTREAM DRX-1, CARESTREAM DRX-Evolution systems and CARESTREAM RIS/PACS from Carestream Health, Inc.

Have News for Us?

Submit your news on the industry, people, or companies.

Forward to a Friend

More Industry Headlines

CBO Releases Reconciliation Act Numbers Coverage in Senate Bill, Reconciliation costs $940 billion, reduces deficit by $138 billion.

Health Care Vote May Come This Weekend Weekend vote is a possibility according to House Majority Leader.

ECR Video Profile: Dunlee, Philips Healthcare David Kuehn of Dunlee presents the company's two new products.

Imaging 100 Preview: The Importance of Banding Together During Health Care Reform Imaging 100 speakers will focus on important health care reform issues.

Congressmen Introduce Bill for Electronic Health Record Interoperability While reform inches along, other legislation progresses.

ECR 2010 Video Profile: Barco DOTmed News stopped by Barco's booth to check out their upcoming medical tablets (developed by FIMI, Barco's recent acquisition) and their latest clinical displays that bring DICOM-compliant viewing outside of the radiologist's office.

CCHIT Comments on ONC's EHR Interim Final Rule The certification organization for electronic health records in the U.S. points out problems in vagueness, complexity of criteria. Also, get a DOTmed exclusive update on CCHIT's testing status.

Health Care Reform Round-Up: More Maneuvers May Be Needed for Passage House leaders said to be considering "self-executing" rule for Senate bill passage.

MEDCAC to Meet on Prostate Determination CMS to review coverage decisions about radiation therapy April 21.

Michigan Legislature Sends Device Re-Use Bill to Governor Bill would prohibit reusing single-use devices.

Nanoparticles and polymers
were used to create a sensor
that can distinguish between healthy,
cancerous and metastatic cells

Chemical "Nose" Knows If We Have Cancer and Whether it's Metastatic

by Lynn Shapiro, Writer
Using a "chemical nose" array of nanoparticles and polymers, researchers at the University of Massachusetts Amherst have developed a fundamentally new, more effective way to differentiate not only between healthy and cancerous cells but also between metastatic and non-metastatic cancer cells. It's a tool that could revolutionize cancer detection and treatment, according to chemist Vincent Rotello and cancer specialist, Joseph Jerry.

An article describing Rotello and colleagues' new chemical nose method of cancer detection appears in the June 23 issue of the journal Proceedings of the National Academy of Sciences online.

Story Continues Below Advertisement
DOTmed Text Ad

Meet Over 100 Directors of Radiology this Spring!

Attend HCP's Radiology & Imaging Conference and "Reverse Trade Show" -- San Diego, CA April 14th to 16th. Meet high-value prospects in a friendly setting. Do more business, make more sales. Call 727-789-9182


Currently, detecting cancer via cell surface biomarkers has taken what's known as the "lock and key" approach. Drawbacks of this method include that foreknowledge of the biomarker is required. Also, as Rotello explains, a cancer cell has the same biomarkers on its surface as a healthy cell, but in different concentrations, a maddeningly small difference that can be very difficult to detect.

"You often don't get a big signal for the presence of cancer," he notes. "It's a subtle thing."

He adds, "Our new method uses an array of sensors to recognize not only known cancer types, but it signals that abnormal cells are present. That is, the chemical nose can simply tell us something isn't right, like a 'check engine light,' though it may never have encountered that type before." Further, the chemical nose can be designed to alert doctors of the most invasive cancer types, those for which early treatment is crucial.

In blinded experiments in four human cancer cell lines (cervical, liver, testis and breast), as well as in three metastatic breast cell lines, and in normal cells, the new detection technique correctly indicated not only the presence of cancer cells in a sample but also identified primary cancer vs. metastatic disease.

In further experiments to rule out the possibility that the chemical nose had simply detected individual differences in cells from different donors, the researchers repeated the experiments in skin cells from three groups of cloned BALB /c mice: healthy animals, those with primary cancer and those with metastatic disease. Once again, it worked. "This result is key," says Rotello. "It shows that we can differentiate between the the three cell types in a single individual using the chemical nose approach."

Rotello's research team, with colleagues at the Georgia Institute of Technology, designed the new detection system by combining three gold nanoparticles that have special affinity for the surface of chemically abnormal cells, plus a polymer known as PPE, or para-phenyleneethynylene. PPE fluoresces or glows as warning light when displaced from the nanoparticle surface.

Continue reading Chemical "Nose" Knows If We Have Cancer and Whether it's Metastatic...
  Pages: 1 - 2 >>

Interested in Medical Industry News? Subscribe to DOTmed's weekly news email and always be informed. Click here, it takes just 30 seconds.

Please Send us your Comments.

Printable Story
Access and use of this site is subject to the terms and conditions of our LEGAL NOTICE & PRIVACY NOTICE
Property of and Proprietary to DOTmed.com, Inc. Copyright ©2001-2010 DOTmed.com, Inc.
ALL RIGHTS RESERVED